2010 Chasing Polio in Pakistan. Nashville, TN: Vanderbilt University Press.
Cohen Marill, M.
2015 After flu vaccine mismatch, calls for delayed selection intensify. Nature Medicine 21:297–298.
Colombini, A., O. Badolo, B. D. Gessner, P. Jaillard, E. Seini, and A. Da Silva
2011 Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine
Daugla, D. M., J. P. Gami, K. Gamougam, N. Naibei, L. Mbainadji, M. Narbé, J. Toralta, et al.
2014 Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal
meningitis and carriage in Chad: A community trial. The Lancet 383:40–47.
2011 How the case against the MMR vaccine was fixed. British Medical Journal 342: c5347.
Delrieux, I., S. Yaro, T. A. Tamekloé, B. M. Njanpop-Lafourcade, H. Tall, P. Jaillard, M. S. Ouedraogo, et al.
2011 Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS
Djibo, S., P. Nicolas, J. M. Alonso, A. Djibo, D. Couret, J. Y. Riou, and J. P. Chippaux
2003 Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000. Tropical Medicine and
International Health 8(12):1118–1123.
Dunn, A. G., D. Arachi, J. Hudgins, G. Tsafnat, E. Colera, and F. T. Bourgeois
2014 Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza. Annals of
Internal Medicine 161:513–518.
Forman, D., C. de Martel, C. J. Lacey, I. Soerjomantaram, J. Lortet-Tieulent, L. Bruni, J. Vignat, et al.
2012 Global burden of human papillomavirus and related diseases. Vaccine 30 (Suppl5): F12–23.
Funk, A., K. Uadiale, C. Kamau, D. A. Caugant, U. Ango, and J. Greig
2014 Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria,
2013–2014. PLoS Currents. 6: ecurrents.outbreaks.b50c2aaf1032b3ccade0fca0b63ee518.
Gagneaux, S., T. Wirth, A. Hodgson, I. Ehrhard, G. Morelli, P. Kriz, B. Genton, T. et al.
2002 Clonal groupings in serogroup X Neisseria meningitidis. Emerging Infectious Diseases 8(5):462–466.
Gagnon, M. A.
2011 Rethinking the social determinants of value in cognitive capitalism. European Journal of Economic and
Social Systems 1–2:119–136.
2014a Meningitis A vaccine support. GAVI Alliance: Types of support. http://www.gavi.org/support/nvs/meningi
Godlee, F., J. Smith, and H. Marcovitch
2011 Wakefield’s article linking MMR vaccine and autism was fraudulent. British Medical Journal 342:c7452.
Graham, J. E.
2008 Facilitating regulation: The dance of statistical significance and clinical meaningfulness in standardizing
technologies for dementia. BioSocieties 3(3):241–263.
Graham, J. E. and A. Mishra
2011 Global challenges of implementing human papillomavirus vaccines. International Journal for Equity in
Health 10 (1):27.
Graham, J. E., A. Borda-Rodrigeuz, F. Huzair, and E. Zinck
2012 Capacity for a global vaccine safety system: The perspective of national regulatory authorities. Vaccine 30
Hamidi, A., C. Boog, S. Jadhav, and H. Kreeftenberg
2014 Lessons learned during the development and transfer of technology related to a new Hib conjugate vaccine
to emerging vaccine manufacturers. Vaccine 32(33):4124–4130.
1990 Ten best readings in …the Bamako Initiative. Health Policy and Planning 5 (2):186–189.
Huzair, F., A. Borda-Rodriguez, and M. Upton
2011 Twenty-first century vaccinomics innovation systems: Capacity building in the global south and the role of
product development partnerships (PDPS). Omics A Journal of Integrative Biology 15(9):539–543.
Hyde, T. B., H. Dentz, S. A. Wang, H. E. Burchett, S. Mounier-Jack, and C. F. Mantel
2012 The impact of new vaccine introduction on immunization and health systems: A review of the published
literature. Vaccine 30(45):6347–6358.
Idoko, O. T., A. Diallo, S. O. Sow, A. Hodgson, A. Akinsola, B. Diarra, F. C. Haidara, Pet al.
2015 Community perspectives associated with the African PsA-TT(MenAfriVAc) vaccine trials. Clinical
Infectious Diseases 61(S5): S416–S421.
MEDICAL ANTHROPOLOGY 429